PRKG1 and pulmonary arterial hypertension: The inhibitory effect of eNOS was not sufficient to completely reduce the expression of ET-1, and therefore a large amount of NO was produced which activated the sGC/PKG pathway to further enhance the role in the prevention and treatment of PAH by liraglutide.